|
Somaxon Pharmaceuticals, Inc. - Company Profile Snapshot
| Company Profile: |
Somaxon Pharmaceuticals, Inc. |
| Ticker: |
SOMX |
| Exchanges: |
NAS |
| 2008 Sales: |
n/a |
| Major Industry: |
Retailers |
| Sub Industry: |
Drug Store Chains |
| Country: |
UNITED STATES |
| Employees: |
22 |
Business Description
Somaxon Pharmaceuticals, Inc.. The Company's principal activity is that of licensing, development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its product candidates are Silenor is in Phase 3 clinical trials for the treatment of insomnia, Nalmefene hydrochloride is in a Phase 2/3 clinical trial for the treatment of pathological gambling and a Phase 2 clinical trial for smoking cessation. The Company is also developing a new formulation of Acamprosate Calcium for the treatment of certain movement disorders.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
